Application Of Autologous Blood Products During Modified Radical Mastectomy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE3

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-12-31

Study Completion Date

2012-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine if the application of autologous (your own blood) blood products during mastectomy improves wound healing and decreases complications following surgery compared to mastectomy without the use of autologous blood products.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prevention of Post-Mastectomy Breast Pain Using Ambulatory Continuous Paravertebral Blocks

NCT01231204

Paravertebral Catheter Insertion Mastectomy Breast Cancer

COMPLETED PHASE4

Accelerated Radiation Therapy After Surgery in Treating Patients With Breast Cancer

NCT01417286

Inflammatory Breast Cancer Invasive Ductal Breast Carcinoma Invasive Lobular Breast Carcinoma +7 more

COMPLETED PHASE2

Delayed-Immediate Breast Reconstruction

NCT00473122

Breast Cancer

COMPLETED PHASE2

Effect of Pectoral Nerve Block on Post-op Pain in Patients Undergoing Mastectomy and Immediate Reconstruction

NCT02913573

Breast Neoplasm

UNKNOWN PHASE2

Can Methylprednisoloneacetate Prevent Seroma After Mastectomy for Primary Breast Cancer

NCT01380912

Breast Cancer

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A frequent complication of mastectomy is seroma formation with rates in the literature reported at 3-50%. Although seroma formation can be considered more of a nuisance than a serious complication, the presence of seroma can lead to wound infection, skin flap necrosis, wound dehiscence, nerve injury, and lymphedema in mastectomy patients.Various approaches to reduce seroma formation have included the use of external compression dressings, ultrasound cutting devices, suction drainage systems, and bovine thrombin. Although some of these interventions have demonstrated efficacy, none has gained widespread acceptance. Investigation of alternative interventions during mastectomy procedures that could reduce the rate of postoperative seroma formation, thereby reducing the likelihood of the onset of more serious complications, still has value to the patient and surgeon. The use of autologous blood products (ABP), in particular platelet rich plasma (PRP), has been advocated for numerous indications. As a surgical tool, ABP are typically applied to the surgical site during the latter stages of the procedure in combination with bovine thrombin. The aim of PRP application is to accelerate the healing cascade via application of elevated cytokine concentrations released during platelet degranulation. It is hypothesized that the elevated cytokine levels will elucidate an accelerated healing response of the affected tissue. Preliminary evidence suggests that this expedited healing response correlates with a reduction in postoperative wound complications. Platelet poor plasma, a by-product of PRP processing, has been advocated as providing additional hemostasis. The majority of the literature discussing clinical applications of ABP to date, has been unblinded and nonrandomized. Although useful as demonstrations of the safety of ABP, this current literature does not truly investigate the efficacy of these applications. There is a need for well-designed, well-controlled studies investigating the application of ABP as surgical tools. It is hypothesized that a significant reduction in postoperative complications, in particular seroma formation, will result due to the use of ABP during these procedures.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Mastectomy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

DOUBLE

Participants Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Application of Autologous Blood Products to surgical site during mastectomy.

Group Type EXPERIMENTAL

Application of autologous blood products.

Intervention Type PROCEDURE

Autologous blood products (platelet rich and platelet poor plasma) produced by the PlasmaxTM Plus Plasma Concentration System will be applied to the surgical site.

2

Standard Modified Radical Mastectomy

Group Type ACTIVE_COMPARATOR

Standard Modified Radical Mastectomy

Intervention Type PROCEDURE

Mastectomy per standard procedure without the application of autologous blood products.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Application of autologous blood products.

Autologous blood products (platelet rich and platelet poor plasma) produced by the PlasmaxTM Plus Plasma Concentration System will be applied to the surgical site.

Intervention Type PROCEDURE

Standard Modified Radical Mastectomy

Mastectomy per standard procedure without the application of autologous blood products.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Patient undergoing a modified radical mastectomy, simple mastectomy or axillary lymph node dissection.
2. Patient signature of informed consent form

Exclusion Criteria

1. Pregnancy
2. \< 18 years of age
3. History of anemia (hemoglobin \< 11.0)
4. History of any blood disorder, deep vein thrombosis, pulmonary emboli or clotting disorders.
5. Un-cooperative patient or patient with neurological disorders who are incapable of following directions or who are predictably unwilling to return for follow-up examinations
6. Allergy to bovine products
7. History of MRSA in last 12 months
8. Communicable disease or diseases that may limit follow- up (e.g. immunocompromised conditions, hepatitis, active tuberculosis)

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No